Additional information on topics for the Joint Meeting of the TSE Advisory Committee and Blood Products Advisory Committee may be found in the following sources:

A. Plasma derivatives and clearance of spiked TSE infectivity or protease-resistant prion protein

1. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999;9(1):3-14.

2. Foster PR. Prions and blood products. Ann Med 2000;32(7):501-13.

3. Foster PR, McLean C, Welch AG, Griffin BD, Hardy JC, Bartley A, et al. Removal of abnormal prion protein by plasma fractionation. Transfus Sci 2000;22(1-2):53-6.

4. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000;78(2):86-95.

5. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000;84(1):77-89.

6. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001;41(4):449-55.

B. Update on vCJD in the UK

1. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001;358(9277):208-9.

2. Cousens S, Smith PG, Ward H, Everington D, Knight RS, Zeidler M, et al. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet 2001;357(9261):1002-7.

3. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM. Epidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great Britain. Proc R Soc Lond B Biol Sci 1998;265(1413):2443-52.

4. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD mortality in Great Britain. Nature 2000;406(6796):583-4.

5. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Assessment of the prevalence of vCJD through testing tonsils and appendices for abnormal prion protein. Proc R Soc Lond B Biol Sci 2000;267(1438):23-9.

6. Huillard d’Aignaux JN, Cousens SN, Smith PG. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science 2001;294(5547):1729-31.

7. Medley GF. Epidemiology. Predicting the unpredictable. Science 2001;294(5547):1663-4.

8. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001;294(5547):1726-8.

9. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358(9277):171-80.

C. BSE in the UK

DEFRA BSE Information, Jan 2002. Public Health.

D. Global control of BSE and vCJD

Joint WHO/FAO/OIE Technical Consultation on BSE, Public Health and Trade. Paris, 11-14 June 2001.

E. Potential for Bovine Spongiform Encephalopathy in the United States

Cohen JT, Duggar K, Gray GM, Kreindel S, Abdelrahman H, HabteMariam T, Oryang D, Tameru B. Evaluation of the Potential for Bovine Spongiform Encephalopathy in the United States. [The Harvard BSE Risk Assessment] Nov 26, 2001.